Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CAH vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$46.36B
5Y Perf.+260.2%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$98.11B
5Y Perf.+404.8%

CAH vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CAH logoCAH
MCK logoMCK
IndustryMedical - DistributionMedical - Distribution
Market Cap$46.36B$98.11B
Revenue (TTM)$250.55B$397.96B
Net Income (TTM)$1.56B$4.34B
Gross Margin3.7%3.4%
Operating Margin0.9%1.3%
Forward P/E19.1x20.5x
Total Debt$9.35B$7.39B
Cash & Equiv.$3.87B$5.69B

CAH vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CAH
MCK
StockMay 20May 26Return
Cardinal Health, In… (CAH)100360.2+260.2%
McKesson Corporation (MCK)100504.8+404.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: CAH vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CAH leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. McKesson Corporation is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
CAH
Cardinal Health, Inc.
The Income Pick

CAH carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 20 yrs, beta 0.03, yield 1.0%
  • Lower volatility, beta 0.03, current ratio 0.94x
  • Beta 0.03, yield 1.0%, current ratio 0.94x
Best for: income & stability and sleep-well-at-night
MCK
McKesson Corporation
The Growth Play

MCK is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 375.1% 10Y total return vs CAH's 175.5%
  • 16.2% revenue growth vs CAH's -1.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs CAH's -1.9%
ValueCAH logoCAHLower P/E (19.1x vs 20.5x)
Quality / MarginsMCK logoMCK1.1% margin vs CAH's 0.6%
Stability / SafetyCAH logoCAHBeta 0.03 vs MCK's 0.04
DividendsCAH logoCAH1.0% yield, 20-year raise streak, vs MCK's 0.3%
Momentum (1Y)CAH logoCAH+31.0% vs MCK's +13.7%
Efficiency (ROA)MCK logoMCK5.3% ROA vs CAH's 2.8%, ROIC 5.4% vs 33.8%

CAH vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

CAH vs MCK — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCAHLAGGINGMCK

Income & Cash Flow (Last 12 Months)

MCK leads this category, winning 5 of 6 comparable metrics.

MCK is the larger business by revenue, generating $398.0B annually — 1.6x CAH's $250.5B. Profitability is closely matched — net margins range from 1.1% (MCK) to 0.6% (CAH).

MetricCAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$250.5B$398.0B
EBITDAEarnings before interest/tax$3.2B$5.8B
Net IncomeAfter-tax profit$1.6B$4.3B
Free Cash FlowCash after capex$4.4B$10.1B
Gross MarginGross profit ÷ Revenue+3.7%+3.4%
Operating MarginEBIT ÷ Revenue+0.9%+1.3%
Net MarginNet income ÷ Revenue+0.6%+1.1%
FCF MarginFCF ÷ Revenue+1.8%+2.5%
Rev. Growth (YoY)Latest quarter vs prior year+11.0%+11.4%
EPS Growth (YoY)Latest quarter vs prior year-19.5%+38.2%
MCK leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

CAH leads this category, winning 4 of 5 comparable metrics.

At 30.5x trailing earnings, CAH trades at a 2% valuation discount to MCK's 31.1x P/E. On an enterprise value basis, CAH's 16.9x EV/EBITDA is more attractive than MCK's 19.9x.

MetricCAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…
Market CapShares × price$46.4B$98.1B
Enterprise ValueMkt cap + debt − cash$51.8B$99.8B
Trailing P/EPrice ÷ TTM EPS30.54x31.14x
Forward P/EPrice ÷ next-FY EPS est.19.08x20.53x
PEG RatioP/E ÷ EPS growth rate0.80x
EV / EBITDAEnterprise value multiple16.91x19.93x
Price / SalesMarket cap ÷ Revenue0.21x0.27x
Price / BookPrice ÷ Book value/share
Price / FCFMarket cap ÷ FCF25.06x18.77x
CAH leads this category, winning 4 of 5 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 6 comparable metrics.
MetricCAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity
ROA (TTM)Return on assets+2.8%+5.3%
ROICReturn on invested capital+33.8%+5.4%
ROCEReturn on capital employed+19.2%+30.5%
Piotroski ScoreFundamental quality 0–966
Debt / EquityFinancial leverage
Net DebtTotal debt minus cash$5.5B$1.7B
Cash & Equiv.Liquid assets$3.9B$5.7B
Total DebtShort + long-term debt$9.3B$7.4B
Interest CoverageEBIT ÷ Interest expense6.38x25.04x
MCK leads this category, winning 5 of 6 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — CAH and MCK each lead in 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $43,011 today (with dividends reinvested), compared to $34,031 for CAH. Over the past 12 months, CAH leads with a +31.0% total return vs MCK's +13.7%. The 3-year compound annual growth rate (CAGR) favors CAH at 34.6% vs MCK's 30.3% — a key indicator of consistent wealth creation.

MetricCAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-3.7%-2.6%
1-Year ReturnPast 12 months+31.0%+13.7%
3-Year ReturnCumulative with dividends+144.1%+121.2%
5-Year ReturnCumulative with dividends+240.3%+330.1%
10-Year ReturnCumulative with dividends+175.5%+375.1%
CAGR (3Y)Annualised 3-year return+34.6%+30.3%
Evenly matched — CAH and MCK each lead in 3 of 6 comparable metrics.

Risk & Volatility

CAH leads this category, winning 2 of 2 comparable metrics.

CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than MCK's 0.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAH currently trades 84.3% from its 52-week high vs MCK's 80.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5000.03x0.04x
52-Week HighHighest price in past year$233.60$999.00
52-Week LowLowest price in past year$137.75$637.00
% of 52W HighCurrent price vs 52-week peak+84.3%+80.2%
RSI (14)Momentum oscillator 0–10038.127.7
Avg Volume (50D)Average daily shares traded1.6M690K
CAH leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

CAH leads this category, winning 2 of 2 comparable metrics.

Wall Street rates CAH as "Buy" and MCK as "Buy". Consensus price targets imply 26.7% upside for CAH (target: $250) vs 25.7% for MCK (target: $1007). For income investors, CAH offers the higher dividend yield at 1.04% vs MCK's 0.34%.

MetricCAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$249.67$1006.50
# AnalystsCovering analysts3331
Dividend YieldAnnual dividend ÷ price+1.0%+0.3%
Dividend StreakConsecutive years of raises2017
Dividend / ShareAnnual DPS$2.04$2.69
Buyback YieldShare repurchases ÷ mkt cap+1.7%+3.2%
CAH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

CAH leads in 3 of 6 categories (Valuation Metrics, Risk & Volatility). MCK leads in 2 (Income & Cash Flow, Profitability & Efficiency). 1 tied.

Best OverallCardinal Health, Inc. (CAH)Leads 3 of 6 categories
Loading custom metrics...

CAH vs MCK: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is CAH or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Cardinal Health, Inc. (CAH) offers the better valuation at 30. 5x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Cardinal Health, Inc. (CAH) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CAH or MCK?

On trailing P/E, Cardinal Health, Inc.

(CAH) is the cheapest at 30. 5x versus McKesson Corporation at 31. 1x. On forward P/E, Cardinal Health, Inc. is actually cheaper at 19. 1x.

03

Which is the better long-term investment — CAH or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +330.

1%, compared to +240. 3% for Cardinal Health, Inc. (CAH). Over 10 years, the gap is even starker: MCK returned +375. 1% versus CAH's +175. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CAH or MCK?

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus McKesson Corporation's 0. 04β — meaning MCK is approximately 27% more volatile than CAH relative to the S&P 500.

05

Which is growing faster — CAH or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CAH or MCK?

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus 0. 7% for Cardinal Health, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus 1. 0% for CAH. At the gross margin level — before operating expenses — CAH leads at 3. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CAH or MCK more undervalued right now?

On forward earnings alone, Cardinal Health, Inc.

(CAH) trades at 19. 1x forward P/E versus 20. 5x for McKesson Corporation — 1. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 26. 7% to $249. 67.

08

Which pays a better dividend — CAH or MCK?

All stocks in this comparison pay dividends.

Cardinal Health, Inc. (CAH) offers the highest yield at 1. 0%, versus 0. 3% for McKesson Corporation (MCK).

09

Is CAH or MCK better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 0% yield, +175. 5% 10Y return). Both have compounded well over 10 years (CAH: +175. 5%, MCK: +375. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CAH and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CAH is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock. CAH pays a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CAH and MCK on the metrics below

Revenue Growth>
%
(CAH: 11.0% · MCK: 11.4%)
P/E Ratio<
x
(CAH: 30.5x · MCK: 31.1x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.